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Abstract 
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Autologous platelet concentrates are widely used in a variety of medical application 
with the aim of enhancing the regeneration of hard and soft tissue. The rationale of this 
clinical use lies in their enriched content of growth factors and other key molecules 
involved in promoting tissue healing.  
This thesis is composed of two different studies having as a common objective the 
evaluation of the biological properties of a platelet concentrate, Pure-Platelet Rich 
Plasma. 
The first part of the thesis was a pre-clinical in vitro study focused on evaluating the 
stimulating activity of P-PRP on human osteoblasts (hObs) and human dermal 
fibroblasts (hDFs).  
hObs and hDFs were grown in a serum-free medium supplemented by P-PRP obtained 
from three different donors. hObs and hDFs proliferation was assessed by cell counting 
and vitality through MTT assays up to 12 days of incubation. hObs osteo-
differentiation was tested after 7- and 14- days of incubation by alkaline phosphatase 
assay.  
Results showed that cells maintained in the presence of P-PRP display an increased 
proliferation rate at 12 days of culture, compared to the standard condition. The 
increased vitality of hObs, induced by P-PRP, noticed after 12 days of culture, was 
comparable of that of control. In contrast, an increased vitality of hDFs, in comparison 
to the control, was observed at 12 days of culture. The addition of P-PRP did not 
further stimulate the enzyme activity either at day 7 and 14. 
The second part of the thesis was a randomized clinical trial that focused on clinical 
and radiographic evaluation of the adjunct of P-PRP in the management of edentulous 
posterior maxillae with a reduced height needing an implant rehabilitation. Clinical 
and radiographic outcomes of two different approaches were compared up to 3 years 
after loading: fixed prosthesis supported by 5 to 8.5 mm-long implants which were 
humidified with P-PRP versus fixed prosthesis supported by 10-mm or longer 
implants bioactivated with P-PRP and placed following maxillary sinus augmentation 
with deproteinized bovine bone mixed with P-PRP.  
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Results showed that both procedures were safe and successful, with comparable 
outcomes. The use of P-PRP did not shift the balance toward one technique over the 
other one, but it may have contributed to make these procedures similar in term of 
clinical and radiographic outcomes.  
Since similar outcomes were reported for both approaches, the most cost-effective 
treatment appears the appropriate and should be advocated. Therefore, when there is 
an alternative for restoring the lost dentition, avoidance of a demanding surgical 
procedure like maxillary sinus augmentation should be considered and recommended. 
In conclusion, results coming from the in vitro study and the randomized clinical trial 
may support the clinical use of P-PRP. It may be beneficial in those situations requiring 
a successful bone and soft tissue regeneration at the site of surgery. 
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Introduction 
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1.1 Autologous platelet concentrates 
1.1.1 General aspects 
Autologous platelet concentrates (APCs) have been widely used in many different 
clinical situations that require a rapid tissue healing and regeneration as it is especially 
the case in oral and maxillofacial surgery, orthopaedics, sports medicine, 
ophthalmology and in the treatment of skin ulcers. APCs are hemocomponents, 
obtained through centrifugation of patient's own blood, in order to collect the most 
active blood components: platelets, fibrin and in certain cases also leukocytes. The final 
product has a platelet concentration higher than the basal level, consequently has an 
increased number of platelet-derived growth factors [1]. The rational of the clinical use 
of such platelet-rich preparations is based upon the concept of exploiting their contents 
enriched of numerous mitogenic platelet-derived growth factors (including platelet-
derived growth factor, [PDGF] transforming growth factor-β [TGF-β], endothelial 
growth factor [EGF], vascular endothelial growth factor [VEGF], insulin-like growth 
factor-1 [IGF-1], basic fibroblast growth factor [FGF], hepatocyte growth factor [HGF]) 
as well as other key molecules in promoting tissue healing (as adhesive proteins, pro-
coagulant factors, cytokines, chemokines and anti-microbial proteins [2-5] to stimulate 
many biological functions such as chemotaxis, angiogenesis, proliferation, 
differentiation (Table 1) in order to enhance hard and soft tissue healing. 
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Table 1. Platelet α-granule contents and their functional categories 
Category Term Biological activities 
Adhesive  
proteins 
VWF + pro-peptide, Fg, Fn, Vn, 
TSP-1, laminin-8 
Cell contact interactions, clotting, 
extracellular matrix composition 
Clotting factors 
and associated 
proteins 
F V/Va, F XI, Gas6, protein S, 
HMWK, AT, TFPI 
Thrombin production and 
regulation, angiogenesis 
Fibrinolytic 
factors and 
associated 
proteins 
Pgn, PAI-I, u-PAm, OSN, α2-AP, 
HRGP, TAFI, α2-M 
Plasmin production and vascular 
modelling 
Proteases and 
anti-proteases 
TIMP-4, MMP-4, inhibitor of FIX, 
PN-II, C1-INH, A1AT 
 
Angiogenesis, vascular modelling, 
regulation of coagulation, regulation 
of cellular behaviour 
Growth factors, 
cytochines,  
chemokines 
PDGF, TGFβ-1 and -2, EGF, IGF-
1,VEGF, bFGF, FGF-2, HGF, 
CCL5, IL-8, MIP-1α, CXCL5, MCP-
3,  ANG-1, IL-1β,  
neutrophil chemoactive protein 
Chemotaxis, cell proliferation and 
differentiation, angiogenesis 
Basic proteins  
and others 
PF4, β-TG, PBP, CTAP III, NAP-2, 
ES 
Regulation of angiogenesis, vascular 
modelling, cellular interactions 
Anti-microbial 
proteins 
TC Bactericidal and fungicidal 
properties 
Others CS-4, AB, Ig Diverse 
Membrane 
glycoproteins 
αIIbβ3, αvβ3, GPIb, PECAM-1, 
most plasma membrane 
constituents, receptors for primary 
agonists, CD40L, TF, P-selectin 
Platelet aggregation and adhesion, 
endocytosis of proteins, 
inflammation, thrombin generation, 
platelet-leukocyte interactions 
Extracted and readapted from Anitua et al. Thromb Haemost 2004;91:4-15 [2] 
 
1.1.2 History of the medical use of platelet concentrates 
1.1.2.1 Fibrin adhesives 
More than 40 years ago these technologies were originally used as sealant-adhesive 
agents in the treatment of haemorrhage with the aim of blocking the blood leakage [6]. 
Subsequently, other molecules involved in the coagulation process were combined to 
such fibrin preparations to improve their adhesive properties. These preparations were 
referred as "platelet-fibrinogen-thrombin mixtures" and were successfully used in 
ophthalmology [7,8], general surgery [9] and neurosurgery [10]. Other authors termed 
them as "gel foam" [11].  
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It is noteworthy that the application of these preparations was essentially related to 
their adhesive properties and the platelets served only to reinforce the fibrin matrix 
architecture. Only several years later, it was developed the concepts that these 
preparations could have healing and regenerative properties. In the late 80's, Knighton 
and coll. [12-14] used the autologous "Platelet-Derived Wound Healing Factors 
(PDWHF)", which was prepared through 2-step centrifugation process, in the 
treatment of chronic non-healing cutaneous ulcers. In 1997, Whitman et al. used 
platelet concentrate referred as "platelet gel" in oral and maxillofacial surgery [15]. 
 
1.1.2.2 Platelet-Rich Plasma 
The term "Platelet-Rich Plasma" (PRP) was, for the first time, introduced by Kingsley et 
al. to describe a thrombocyte concentrate [16] used for the treatment of severe 
thrombopenia. However, the use of PRP term really started with Marx in 1998 [1] when 
he published a comparative clinical study in which the PRP regenerative potential was 
demonstrated during a mandibular reconstruction. Afterwards, the PRP product was 
then associated with the concept of platelet growth factors and their potential 
contribution to the enhancement of tissue healing.  
According to the PRP protocol, the blood is collected in tubes containing 
anticoagulants and processed by two centrifugation steps. Figure 1 illustrates in details 
the specific protocol [17]. The final PRP product can be applied to the surgical site with 
a syringe or be activated by thrombin and/or calcium chloride to trigger platelet 
activation and to stimulate the fibrin polymerization.  
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Figure 1. Protocol for PRP production.  
After blood collection with anticoagulants, the first centrifugation at low forces (soft 
spin) allows the separation of blood into three distinct layers: red blood cells at the 
bottom, acellular plasma (PPP, Platelet-Poor Plasma) in the upper portion and a 
whitish layer called buffy coat located between them containing the highest 
concentration of platelets and leukocytes. For the production of Pure-PRP (P-PRP), PPP 
and the superficial buffy coat layer are transferred into another tube and centrifuged at 
high forces (hard spin) after which most of the PPP and leukocytes are discarded and 
the final P-PRP can be collected. For the production of PRP rich in leukocytes (L-PRP), 
PPP, the entire buffy coat layer and some residual red blood cells are collected and 
transferred in another tube to be hard spin centrifuged. To obtain the final L-PRP, PPP 
is discarded leading to a L-PRP that contains the buffy coat with most of the platelets 
and leukocytes, some residual red blood cells and PPP. Adapted from Dohan Ehrenfest 
et al. Trends Biotechnol 2009;27:158-67 [17]. 
 
1.1.2.3 Platelet-Rich Fibrin  
Choukroun and coll. developed in 2011, concomitantly to the introduction of PRP, 
another form of platelet concentrate, named Platelet-Rich Fibrin (PRF) [18]. Here, the 
blood is collected in tubes in the absence of anticoagulant and centrifuged with 
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moderate forces for 12 minutes. Afterwards three layers are formed: red blood cells 
and acellular plasma are located, respectively, at the bottom and at the top of the tube, 
and the fibrin clot, positioned between them, is PRF (Figure 2). Since the formation of 
the PRF clot naturally occurs within the tube, it has a strong fibrin matrix in which 
most of the platelets and leukocytes are embedded [19].  
 
 
 
 
 
 
Figure 2. Protocol for PRF production. Adapted from Dohan Ehrenfest et al. J 
Periodontol 2010;81:546-55 [19]. 
 
1.1.2.4 Platelet-Rich in Growth Factors 
In parallel to the introduction of PRP and PRF, Anitua in 1999 proposed another 
platelet concentrate protocol, denominated Plasma Rich in Growth Factors (PRGF) [20]. 
According to that, blood is collected in tubes containing 3.8% trisodium citrate as 
anticoagulant. After a centrifugation at 580g for 8 minutes, red blood cells and buffy 
coat layer are deposited at the bottom of the tube, and the plasmatic component above. 
The plasmatic component is then manually separated into two fractions. The lower 
portions of about 2 ml above the buffy coat, is the PRGF, while the upper portion is the 
Plasma Poor in Growth Factors (PPGF) (Figure 3). The final PRGF product may be 
applied as a liquid fraction to the target site or may be activated by adding 10% CaCl2 
milliliter to induce the clot formation [21].  
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Figure 3. Process of PRGF production. Details in the text. [Adapted from Anitua Pract 
proced aesthet dentist 2001;13:487-493 [21]. 
 
1.1.3 Technical differences between PRGF, PRP and PRF 
PRGF differs from PRP for the following technical aspects: 
1) blood volume drawn is minimal (5-40 ml) 
2) requires a single centrifugation for the preparation 
3) does not contain leukocytes  
4) does not contain pro-inflammatory cytokines 
5) platelet concentration is reduced (2-3 threefold the baseline) 
 
In addition PRGF also differs from PRF for these features:  
1) different products can be obtained (liquid, fibrin clot)  
2) PRGF liquid can be combined with bone graft materials for bone regeneration 
procedure  
 
Differences between PRP and PRF are listed below: 
1) PRP preparation requires 2 centrifugations 
2) different products can be obtained (liquid and fibrin clot) 
3) PRP liquid can be mixed with bone graft materials for bone regeneration procedures. 
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1.1.4 Current classifications of autologous platelet concentrates 
Over the last 20 years, autologous platelet concentrates have been extensively 
investigated both in vitro and in vivo in a wide variety of clinical applications. 
Concomitant to that, multiple systems for their preparation have been developed and 
several different commercial products, as PRP, PRF and PRGF were briefly described 
previously, have been introduced in the market. The direct consequence of such 
growing interest is that a huge number of preparation protocols, commercial kits and 
several different centrifuges are commercially available. Therefore, due to the different 
existing methods of preparation, various types of platelet concentrates differ in cellular 
composition, physical characteristics and presumably biological activity. For these 
reasons, three classifications have been proposed [17,22,23] to better define each 
product. A scientific terminology, instead of the commercial names, has been adopted 
in order to avoid an inaccurate use of these terms. 
 
1.1.4.1 Dohan Ehrenfest classification 
According to the classification proposed by Dohan Ehrenfest and coll. [17], autologous 
platelet concentrates can be divided into 4 categories based upon cell contents, fibrin 
matrix architecture and density [Figure 4]:  
1) Pure Platelet-Rich Plasma  (P-PRP) – plasma rich in platelets without leukocytes 
with low-density fibrin network after activation; 
2) Leukocyte- and Platelet-Rich Plasma (L-PRP) – plasma rich in platelets with 
leukocytes and a low- density fibrin network after activation;  
3) Pure Platelet-Rich Fibrin (P-PRF) – high density fibrin matrix rich in platelets 
without leukocytes; 
4) Leukocyte- and Platelet-Rich Fibrin  (L-PRF) – high density fibrin matrix rich  in 
platelets with leukocytes.	 
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Figure 4. Schematic view of the matrix and cellular composition of the four types of 
platelet concentrates according to Dohan Ehrenfest Classification.  
Leukocytes are represented as blue circles and fibrin as yellow fibres; platelet 
aggregates  are the light-grey circles and are assembled on the fibrin fibres. [Images 
taken from Dohan Ehrenfest et al. Trends Biotechnol. 2009;27:158-67 [17].  
 
1.1.4.2 Mishra classification 
Mishra et al. [22] proposed a classification used especially in the field of sport medicine 
in which platelet concentrates are divided into 4 groups on the basis of platelets and 
leukocytes concentration and whether or not the PRP activation is performed (further 
details are summarized in Table 2).  
Table 2. Mishra classification of Platelet Rich Plasma 
 White Blood Cells  Activation  Platelet 
Concentration  
Type 1 Increased  No activation  A. ≥ 5x       B. < 5x 
Type 2 Increased Activated  A. ≥ 5x       B. < 5x 
Type 3 Minimal or no WBC No activation  A. ≥ 5x       B. < 5x 
Type 4 Minimal or no WBC Activated  A. ≥ 5x       B. < 5x 
Adapted from Mishra et al. Curr Pharm Biotechnol 2012;13:1185-95 [22] 
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1.1.4.3 PAW classification 
The third proposed classification is called PAW (Platelets, Activation, White cells) [23] 
and is based on three parameters: the exact number of platelet quantity, platelet 
activation mode and presence of white blood cells (Figure 5). 
 
Figure 5. PAW classification of PRP [Adapted from DeLong et al. Arthroscopy 
2012;28:998-1009 [23]. 
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1.2 Clinical evidence of the efficacy of autologous platelet 
concentrates in oral regenerative surgical procedures 
1.2.1 General aspects  
In the last couple of decades, it has been observed a growing interest in the use of 
autologous platelet concentrates during oral regenerative surgical procedures as an 
adjunctive tool to enhance the hard and soft tissue healing. The following paragraph 
will summarize the recent evidence on the efficacy of autologous platelet concentrates 
in the dental field. Healing of post-extraction sockets, treatment of periodontal defects, 
treatment of immature necrotic teeth, sinus lift augmentation and implantology will be 
discussed.  
 
1.2.2 Alveolar post-extraction healing 
A recent systematic review evaluated the efficacy of autologous platelet concentrates in 
enhancing alveolar socket healing after tooth extraction. Beneficial effects were 
generally reported in terms of better soft tissue healing, better clinical and histological 
epithelialisation of wound margins and a faster wound closure, although the 
heterogeneity of the data could not allow a meta-analysis. Regarding the bone 
formation, the qualitative synthesis of the histological analyses reported a better bone 
quality in those biopsies retrieved from platelet concentrate treated sites. Furthermore, 
the meta-analysis of the histomorphometric evaluation of the bone formation 
(performed in only two of the included studies), revealed that sites treated with 
platelet concentrate showed a statistically significant greater proportion of new bone 
than the controls, at three months of follow-up. Even though the results of the meta-
analysis are positive suggesting a beneficial effect of autologous platelet concentrates 
on bone formation, caution should be paid on interpreting such results since the 
available evidence are scarce and of limited quality [24].  
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1.2.3 Periodontal defects 
Several systematic reviews and some meta-analysis evaluated the efficacy of 
autologous platelet concentrates in the treatment of periodontal defects including 
intrabony defects, gingival recessions and furcation defects [25-33]. Beneficial effects on 
clinical and radiographic outcomes in the treatment of infrabony defects were 
reported, although it emerged a high heterogeneity among the clinical studies in terms 
of outcomes evaluated and bioactive agents/procedures combined with autologous 
platelet concentrates [25,28,30-32]. Furthermore, two meta-analyses [28,30] concluded 
that PRP might exert positive adjunctive effects in the surgical treatment of such 
defects when combined with grafting materials, but no adjunctive effects in association 
with the guided tissue regeneration technique that may mask the PRP effect. 
Regarding the autologous platelet concentrates' effect on gingival recessions, very few 
systematic reviews have been conducted, presumably due to the limited data about it. 
PRP or PRF did not show any clinical improvements in the treatment of gingival 
recessions or furcation defects [28,33].  
 
1.2.4 Endodontics  
Platelet concentrates have been recently used in the clinical treatment of immature 
necrotic teeth, with the aim of regenerating the intracanal pulp and stimulating tooth 
development, as well as in the surgical treatment of teeth with apical periodontitis to 
enhance healing of periapical tissues. Clinical evidence on the benefits of the use of 
platelet concentrates in these pathologies exists but scarce. Our recent systematic 
review concluded that periapical healing and apical closure were improved in those 
immature necrotic teeth treated with PRP compared to the control group without PRP, 
even though not statistically significant, and a significant better thickening of dentinal 
walls and root lengthening were also reported [34]. However from the histological 
point of view, it seems that a true regeneration of necrotic pulp tissue of either mature 
or immature teeth were not achieved after using platelet concentrates. In fact, the 
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neoformed intracanal tissues were mainly cemento-like, bone-like and connective 
tissue. Root canals were repopulated with living tissue that only marginally resembled 
the original pulp. Despite this, the root maturation may be achieved and teeth function 
is not compromised [35]. 
 
1.2.5 Sinus lift augmentation 
The use of platelet concentrates in association with grafting material during a maxillary 
sinus augmentation reported conflicting results in both preclinical and clinical studies 
[36-42]. A recent meta-analysis documented that PRP combined to graft materials, in 
this type of surgical procedure, had no adjunctive effect on bone formation, on implant 
survival and implant stability as well as it did not show any statistically significant 
differences on marginal bone loss or alveolar bone height, compared to the bone graft 
alone [43]. Similar conclusions were also reported in other systematic reviews [44,45]. 
However another meta-analysis reported opposite conclusions concerning the bone 
formation supporting the use of PRP for sinus bone graft [46]. Furthermore, beneficial 
effects on soft tissue healing as well as reduction of post-operative discomfort were 
often reported [44]. 
 
1.2.6 Implantology  
As it is claimed that platelet concentrates may promote bone regeneration, several 
animal studies have been conducted to assess the PRP effect on the osseointegration 
process, through histological and histomorphometrical evaluation, but controversial 
results have been reported. In fact, some studies did not demonstrate any advantages 
of PRP over non-PRP control groups at stimulating faster bone formation or higher 
bone-implant contact [47-49]. By the contrast, histomorphometric analyses of the bone-
implant interface in the early healing phase after implantation (6 or 8 weeks) revealed a 
significantly higher percentage of bone-implant contact in implants coated with liquid 
PRP formulation compared to those not PRP-bioactivated [50-52]. In addition to being 
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time dependent, PRP effect is also site dependent since its effect has been reported to 
decrease with increasing distance from the site of application [52]. Similarly, liquid-
PRP showed a tendency to increase the bone apposition to roughened titanium 
implants during early healing phase [53,54].  
Clinical studies reported a higher bone formation around the implants [55] and a good 
preservation of the alveolar crest around post-extraction implants [56,57] when APCs 
were used.  
APCs have been also combined with several different types of grafting materials 
during regenerative procedures associated with implanto-prosthesis rehabilitations, 
showing satisfying results and positive patient-related outcomes [58-62]. A long-term 
clinical study (10-12 y) on short implant placement in association with PRGF, reported 
an implant survival rate of 98.9% and marginal bone loss inferior to 1 mm [63].  
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1.3 Management of reduced residual crestal height in the posterior 
maxillary region. Long implants in augmented sinus or short 
implants without augmentation? 
 
Implant placement is a treatment option for partially or totally edentulous jaws. 
Following tooth loss, physiological progressive resorption occurs in the alveolar bone, 
which in case of maxillary posterior regions, leads to an insufficient bone volume 
making unable the placement of dental implants of standard length (≥10 mm). Such 
reduced bone height issue in posterior maxilla may be overcome by sinus lift 
procedure that aims at creating a thicker layer of bone at the basis of the sinus cavity; 
the augmentation of the sinus cavity is performed with autogenous bone or 
biomaterials or both [64]. Maxillary sinus augmentation is the most predictable of the 
surgical techniques used to re-establish the ridge height for the implant placement 
needed to supporting a fixed prosthesis [65].  Alternative techniques to the challenging 
procedure of sinus augmentation were proposed. Among these, placement of short 
implants of reduced length (4-8.5 mm) represents a less complex surgery, cheaper and 
faster option treatment with a reduced morbidity and a high implant survival rate 
[66,67].  
Currently, there is no evidence of superiority of one technique over the other one. 
Evidence of moderate quality on the evaluation of the comparison between short 
implants vs. long implants in augmented sinus exists, but it was unable to conclude 
that sinus lift procedures, in bone with residual height of 4-9 mm, is more successful 
than placing short implants without sinus augmentation at reducing prosthesis or 
implant failure, up to one year after loading, as documented in a Cochrane review [64].  
High implant and prosthesis survival rates for short implants and long implants in 
association with sinus lift were reported in several systematic reviews, although with 
no statistically significant differences [67-70]. In addition, no statistical differences were 
also observed for marginal bone loss [67-69]. However, due to the complexity of the 
technique, increased surgical time and cost [71], increased post-operative morbidity, 
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and also higher risks of complications were reported for sinus elevation procedure [64, 
67, 70].  
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1.4 Rationale of the thesis  
In the last years, the interest of our research group has been focused on investigating 
the use of P-PRP in several oral surgical procedures. Several clinical- and in-vitro 
studies as well as systematic reviews have been conducted for assessing the efficacy of 
P-PRP in the dental field.  
 
1.4.1 Pre-clinical findings on P-PRP 
Some in-vitro studies and one systematic review on pre-clinical studies documented 
that autologous platelet concentrates may have an antimicrobial activity against some 
oral microorganisms. This antibacterial effect may contribute at reducing the incidence 
of post-operative infections [72-74].  
In another in-vitro study, proliferative and differentiative capacities of human adipose-
derived stem cells (hASCs) were tested after being cultured in the presence of P-PRP. 
Platelet-rich preparations promoted hASCs cell viability up to 12 days and 
differentiation toward the osteogenic lineage at early phase (day 7) [75].  
 
1.4.2 Clinical findings on P-PRP 
From the clinical point of view, some randomized clinical trials performed by our 
group showed a significant reduction in the post-operative pain and inflammation in 
association with the use of P-PRP in patients treated for periradicular surgery or 
maxillary sinus augmentation [76-78].  
In particular, preliminary results of a randomized clinical study documented that the 
adjunctive use of P-PRP to the maxillary sinus augmentation had a noticeable 
beneficial effects in patient’s quality of life in the first post-operative days after surgical 
procedure. In fact, a significant reduction in the perceived pain, tissue swelling, 
hematoma formation as well as functional activities was reported when P-PRP was 
mixed to the deproteinized bovine bone graft material and applied as a membrane 
covering the graft, compared to the standard maxillary sinus augmentation without P-
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PRP [78]. Furthermore, a split-mouth histological and histomorphometric study 
investigating regenerated bone biopsies taken 6 months after bilateral maxillary sinus 
augmentation showed a higher newly formed bone volume in sites treated with 
deproteinized bovine bone plus P-PRP as compared to sites augmented with bovine 
bone alone (30.70% ± 7.89% (range, 18.30%–39.99%) in the P-PRP group versus 22.72% 
± 9.21% (range, 11.45%–33.30%) in the control group) [79]. 
 
1.5 Aims of the thesis 
The first aim of the thesis was to proceed on testing further in-vitro inductive capacities 
of P-PRP. Therefore, it was evaluated the in-vitro ability of P-PRP to stimulate vitality 
and cell growth of terminally differentiated cells, as human osteoblasts (hObs) and 
human dermal fibroblasts, since these cellular processes are key-events in tissue 
healing and regeneration. Furthermore, hOb differentiation toward the osteogenic 
lineage was also tested. 
Considering that (a) the adjunct of P-PRP in maxillary sinus augmentation has a 
beneficial effect due to the reported better patients’ related outcomes, and (b) there is 
scarce evidence for a clear superiority of sinus augmentation over the use of short 
implants in case of limited bone volume in the posterior maxilla, it appeared 
interesting to study whether the adjunctive use of P-PRP during these two different 
surgical procedures might shift the balance toward one technique. 
Therefore, the second aim of the thesis was to compare clinical and radiographic 
outcomes of these two approaches for the rehabilitation of edentulous posterior 
maxilla of reduced height: fixed prosthesis supported by 5-8.5 mm-long implants 
which were humidified with P-PRP versus fixed prosthesis supported by 10-mm or 
longer P-PRP bioactivated implants placed after maxillary sinus augmentation with 
deproteinized bovine bone mixed with P-PRP.  
The null hypotheses were: (1) no differences between the two groups regarding 
prosthesis and implant survival and success rates; (2) no differences in marginal bone 
loss, complications, bleeding on probing, presence of inflammation and plaque 
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between the two groups. This thesis reports data of a randomized clinical study up to 3 
years after loading.  
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Chapter II: 
Materials and Methods 
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2.1 The in-vitro study  
2.1.1 Preparation of Pure-Platelet Rich Plasma (P-PRP)  
Blood from healthy donors was collected in 9-ml laboratory tubes (BTI blood collecting 
tubes®) with 3.8% sodium citrate (m/v) and processed according to Anitua’s protocol 
[20] whose details were already reported in a previous paragraph (1.1.2.4 pag.12). 
Platelets count was performed using a hematology analyzer (Sysmex, XE-2100, 
Norderstedt, Germany). PRGF was activated using 50 µl of 10% CaCl2 per milliliter [21] 
and immediately aliquoted and stored at -80°C until use. After being thawed at 37°C in 
a water bath for few minutes, it was incubated at 37°C for 30 minutes, triggering 
platelet activation and growth factors release and then used as supplement to the 
culture medium. 
 
2.1.2 Cell cultures 
All cells used in this study derived from discarded tissues obtained from healthy 
donors after their written consent and Institutional Review Board approval (IRCCS 
Galeazzi Orthopaedic Institute PQ 7.5.125, version 3, 14.05.2012). 
Human osteoblasts (hObs) were isolated from cortical bone of two male patients (age 
43-57 years) undergoing osteotomy. Bone fragments were digested for 60 minutes with 
collagenase type II (0.003%) at 37°C and hObs were plated and maintained in basal 
medium supplemented with 10% fetal bovine serum (FBS), 50 U/ml penicillin, 50 
mg/ml streptomycin and 2 mM L-glutamine. Plastic culture flasks-adherent hObs were 
selected during subsequent passages. The fibroblast-like morphology displayed by the 
isolated cells was checked by phase-contrast microscopy and the doubling time was 
calculated as ln(N/N0)/ln2, where N is the number of counted cells and N0 represents 
the number of plated ones. Cell viability was tested by means of 3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) test, while the colony-
forming unit-fibroblast (CFU-F) frequency was established by counting individual 
colonies (of at least 20 cells) compared to the number of seeded cells. hObs were 
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characterized immunophenotypically by FACS Calibur flow cytometer (BD Biosciences 
Europe, Erembodegem, Belgium). Cells were CD14, CD45, CD73, CD90, CD105 and 
CD271 positive.  
Human dermal fibroblasts were obtained from a 46-year-old female patient 
undergoing abdominoplastic surgery. Tissue was digested for 6 hours in DMEM and 
0.1% collagenase I at 37°C and hDFs-1 were separated by centrifugation (1200 g for 10 
minutes), filtered, and plated (100,000 cells/cm2) in complete medium. The fibroblast-
like morphology displayed by the isolated cells was checked by phase-contrast 
microscopy and the doubling time was calculated as (t2-t1)_ln2/ln (N/N0), where N is 
the number of counted cells and N0 represents the number of plated ones. Cell 
viability was tested by means of 3-[4,5-dimethylthiazol-2-yl]-2,5- diphenyltetrazolium 
bromide (MTT) test. Human dermal fibroblasts were characterized in vitro and their 
multilineage differentiation potential into adipogenic, osteogenic, and chondrogenic 
lines was also confirmed (data not shown). All cells were maintained in a humidified 
atmosphere at 37°C with 5% CO2 until confluence. 
 
2.1.3 Cell Proliferation and viability 
Cell count: From passage 1 to 3 in culture, cells were detached with 0.5% trypsin/0.2% 
EDTA and plated at a density of 8X103cells/cm2 in 6-well tissue-culture plates. Cells 
were starved for 24 hours, then culture medium was replaced by medium 
supplemented with either 5% of P-PRP or 10% FBS (CTRL). At days 4, 8, 12, cells were 
counted in a Burker chamber considering also trypan blue exclusion. MTT assay: hObs 
and hDFs, derived from the counting assays at day 4, were used for vitality evaluation. 
From passage 3 to 5 cells were plated at a density of 1.5X104 cells/cm2 in 96-well tissue 
culture plates in the presence of either 5% P-PRP or 10% FBS. After 5 and 12 days in 
culture, 0.5 mg/mL MTT (3-[4,5-dimethylthiazol- 2-yl]-2,5-diphenyltetrazolium 
bromide) was added and incubated for 4 hours at 37 °C. The formazan precipitate was 
solubilized with 100% dimethylsulphoxide and the absorbance read at 550nm with a 
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Celbio plate reader. For the proliferation and viability test, cell cultures were 
performed in duplicates. 
 
2.1.4 Osteogenic differentiation  
From passage 1 to 3, hObs were plated in 24-well tissue-culture plates at a density of 
7.5X103 cells/cm2 for 7 days and 5X103 cells/ cm2 for 14 days and let adhere overnight in 
control medium. After being washed and cultured for 24 hours in serum-free medium, 
either 2.5% P-PRP or 10% FBS (CTRL) was added. Then hObs were osteo-induced to 
differentiate with 10 nM dexamethasone, 10 mM glycerol-2-phosphate, 150 µM L-
ascorbic acid-2-phosphate, 10 nM cholecalciferol (OSTEO) [80]. Cells were culture for 7 
and 14 days before the biochemical analyses. ALP assay- enzymatic activity was 
measured at day 7 and 14, cells were lysed with 0.1% Triton X-100 and protein 
concentrations were determined by BCA protein assay (Pierce Biotechnology, 
Rockford, Ill., USA). 1 mM p-nitrophenylphosphate in alkaline buffer (100 mM 
diethanolamine and 0.5 mM MgCl2, pH 10.5) [81] was added to the cell lysate and 
incubated at 37°C. The reaction was stopped with 1N NaOH and absorbance read at 
405nm with a Wallac Victor II plate reader. ALP activity was then normalized respect 
to each sample protein concentration. Reagents, when not otherwise indicated, were 
provided by Sigma-Aldrich, Milan, Italy. 
 
2.1.5 Statistical analysis 
Data are expressed as means ± SE and statistical analysis (unpaired Student’s t-test) 
was performed by using GraphPad Prism 5.03 (GraphPad Software, San Diego, Calif., 
USA). Differences were considered significant at p<0.05. 
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2.2 Randomized clinical study 
The present randomized clinical trial was approved by the ethical committee of the 
Lombardy region and conducted at the Dental Clinic of IRCCS Istituto Ortopedico 
Galeazzi, Milan, Italy. All patients were treated following the principles embodied in 
the World Medical Association Helsinki Declaration of 1975 for biomedical research 
involving human subjects, as revised in 2000 [82] and all surgeries were performed by 
one highly experienced clinician (Dott. Silvio Taschieri) with more than 10 years of 
activity in the implant dentistry field. 
 
2.2.1 Patients inclusion criteria  
• Patients older than 18 years, able to sign an informed consent form and in good 
health (classified as ASA 1-2 following the American Society of 
Anaesthesiologists classification) 
• Patients with posterior edentulous maxilla who needed the augmentation of the 
maxillary sinus floor in order to be rehabilitated by means of fixed implant-
supported prostheses 
• Bone height in the posterior maxilla ranged from 4 to 7 mm as determined by 
preliminary CT evaluation 
2.2.2 Patients exclusion criteria 
• Presence of systemic conditions or pathologies representing contraindication to 
oral surgery and any disease affecting the bone metabolism 
• Presence of active infection or inflammation in the area intended for sinus floor 
augmentation or implant placement such as any form of maxillary sinusitis 
• Pregnant or nursing women 
• Inadequate oral hygiene and poor motivation  
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2.2.3 Study design 
Eligible participants were randomly allocated to receive one of the following 
treatments: test group received implants with a length inferior to 8.5 mm (BTI, 
Biotechnology Institute, Vitoria, Spain) in combination with P-PRP, and control group 
received sinus lift augmentation using deproteinized bovine bone as grafting material 
mixed with P-PRP (Bio-Oss®, Geistlich) and after 6-10 months (in case of a residual 
bone volume and density sufficient to provide optimal implant primary stability, 
implant placement was performed simultaneously to the sinus lift), implants longer 
than 8.5 mm were inserted in combination with P-PRP. Clinical and radiographic 
evaluations were scheduled at 6 and 12 months after prosthesis delivery and yearly 
thereafter up to three years of follow up. Diagram of the study design is illustrated in 
Fig. 6. 
 
 
Figure 6. Study design  
 
2.2.4 Sinus surgery (control group) 
One hour before surgery, 2 g of amoxicillin and clavulanic acid (Augmentin, Roche, 
Milan, Italy) were given to patients as prophylactic regimen. After administration of 
local anesthesia with 4% articaine and adrenaline (1:100,000), a trapezoidal flap was 
elevated after one horizontal incision in the middle portion of the edentulous mucosa 
of the posterior maxilla and two vestibular vertical incisions extending apically to the 
muco-gingival junction were performed. If needed, a periosteal incision was also 
performed to reduce the tensile stresses to the flap. After creation of a lateral window 
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using a piezoelectric device, the Schneiderian membrane was initially detached, 
starting from the mesial wall and then from the distal one using specific membrane 
elevators. Afterwards, a P-PRP clot was placed above the membrane surface and 
continued until the membrane detachment [83]. The absence of membrane perforations 
was assessed. The cavity was then filled with deproteinized bovine bone matrix as 
grafting materials mixed with activated P-PRP. After that, flap was repositioned and 
sutured. Patients were instructed to avoid any activity that could change the sinus 
cavity pressure for 10 days after surgery, as for example sneezing with the mouth 
closed, blowing the nose. Besides, patients had to avoid eating hard and soft foods and 
smoking. Postoperative instructions were: gently rinse with 0,2% chlorexidine 
digluconate solution twice a day for 10 days to plaque control; assumption of pain 
relief medications in case of needed and antibiotic therapy with amoxicillin+ clavulanic 
acid 1 g twice a day for 1 week. 
 
2.2.5 Implant surgery (both groups) 
2.2.5.1 Preparation of P-PRP 
In patients allocated to both groups, P-PRP was prepared according to the Anitua’s 
protocol as previously described in details in section 1.1.2.4, pag. 14. Prior to insertion, 
all implants were embedded in liquid P-PRP to bioactivate the implant surface [50]. 
 
2.2.5.2 Surgical procedure 
One hour before surgery, all patients received as prophylactic regimen 2g of 
amoxicillin and clavulanic acid (Augmentin®, Roche, Milan, Italy) and rinsed with 
0,2% chlorhexidine mouthwash for 2 min. The procedure was carried out under local 
anaesthesia using with articaine (4%) + adrenaline (1:100,000).  
After flap elevation, implant site preparation and insertion were performed according 
to the protocol provided by the manufacturer BTI Biotechnology Institute, Vitoria, 
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Alava, Spain). After being embedded with liquid P-PRP to bioactive the implant 
surface, short implants (length ≤ 8.5 mm) and implants longer than 10 mm were 
installed, in test and control group, respectively. In control group, implants were 
inserted after waiting 6-10 months from the sinus lift procedure to allow the healing of 
the graft material.  
Flaps were then repositioned and secured with sutures. Implants were left to heal in a 
submerged way. Standard pharmacological protocol was prescribed: nimesulide 
100mg twice daily for pain control if needed and chlorhexidine digluconate 
mouthwash 0.2% twice daily for 1 week for plaque control. A soft diet was 
recommended, avoiding contact of the surgically involved zone with food for a few 
days if possible. 
 
2.2.6 Prosthetic phase 
A surgical re-entry procedure was performed 4-6 months after implant insertion. 
Elevation of full thickness flaps was executed to have access to the marginal portion of 
the implant sites and to replace the healing caps with a healing abutment. Prosthetic 
procedures were performed. 
 
2.2.7 Radiographic examination 
A radiograph was taken at entry, immediately after surgery (baseline), at the prosthetic 
phase, and at each follow-up visit (after 6 and 12 months of prosthesis function and 
yearly thereafter). Radiographs of the prosthetic phases were taken using a long-cone 
paralleling technique and individual trays to ensure reproducibility. A specific image 
analysis software (ImageJ version 1.46, National Institutes of Health, Bethesda, MD, 
USA; http://rsb.info.nih.gov/ij/) was used to perform measurements of marginal bone 
level around implants at the mesial and distal aspects. The implant neck was the 
reference for each measurement. Implant length was used for calibration. All the 
radiographs were analysed by an independent evaluator (AL).  
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2.2.8 Primary and secondary outcomes 
Primary outcomes assessed were implant and prosthesis survival defined as the 
implant and prosthesis were still in function, without mobility. 
Secondary outcomes were:  
• Occurrence of any biological or prosthetic complications 
• Mesial and distal changes of marginal bone level, measured on periapical 
radiographs as described previously (radiographic examination in section 2.2.7) 
• Assessment of the following clinical parameters: presence of plaque; presence 
of bleeding on probing; presence of inflammation; presence of peri-implant 
radiolucency; presence of prosthesis mobility 
 
2.2.9 Statistical analysis 
Descriptive statistical analysis was performed. Data were synthesized using the mean 
value and standard deviation for the quantitative variables. Life table analysis was 
used to calculate the cumulative survival rate on implant basis. Implant survival was 
evaluated according the following criteria: presence of the implant in the patient's 
mouth, absence of peri-implant radiolucency, no recurrence or persistent peri-implant 
infection, no complain of pain and of neuropathies or paraesthesia. 
Unpaired Students' t-test was used to compare the means between two groups, while 
Fisher's exact test was used for nominal data and survival rates. A p-value below 0.05 
was considered statistically significant.  
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Chapter III: 
Results 
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3.1 In vitro study 
3.1.1 Platelet concentration of Pure-Platelet Rich Plasma 
Mean baseline platelet concentration of three volunteer donors was 259.40×103 
platelets/µl (range 225-291×103 platelets/µl). After centrifugation, mean platelet 
concentration of P-PRP was 485.40×103 platelets/µl (range 384-584×103 platelets/µl), 
with a mean increase of 1.9-fold (Table 3). 
 
3.1.2 Cell Proliferation of hObs and hDFs 
Human osteoblasts (hObs) maintained in the presence of 5% P-PRP and detached 
every 4 days had a similar proliferation rate of those grown in control culture condition 
(CTRL) at 4 and 12 days of cell culture, while at 8 days they showed a lower 
proliferation rate compared to the CTRL ones (Figure 7). 
Figure 7. The effect of P-PRP 
on hOb proliferation.  
Proliferation was assessed after 
cell detachment every 4 days. 
CTRL: Control; P-PRP: Pure- 
Platelet Rich Plasma 
 
Table 3. Clinical data of blood donors 
Variable Number or Mean ± SD (range) 
Donors 3 
Age (years) 26.2 ± 2.6  
Platelets of blood (103/µl) 259.40 ± 29.98 (225-291) 
Platelets of P-PRP (103/µl) 485.40 ± 79.27 (384-584) 
P-PRP: Pure-Platelet Rich Plasma. Brini et al. J Craniofac Surg 2016;27:656-61 [84] 
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By contrast, when hObs were cultured in the presence of 5% P-PRP for 12 days without 
being detached, a 1.2-fold increase in their growth was observed compared to the 
CTRL (Fig. 8).  
 
Figure 8. The effect of P-PRP 
on hOb proliferation.  
Proliferation was assessed at 12 
days without cell detachment. 
CTRL: Control; P-PRP: Pure- 
Platelet Rich Plasma 
 
Human dermal fibroblasts (hDFs) cultured with 5% P-PRP behaved similarly to hObs. 
In fact, at early time points it was not observed any appreciable cell number increase of 
hDFs, while after 12 days of P-PRP, their mean proliferation rate increased 3-fold 
compared to the control medium (Figure 9) with a pronounced growth peak.  
 
Figure 9. The effect of P-PRP 
on hDF proliferation. 
 
 
 
 
Cell growth increase observed after 12 days of culture with P-PRP was not statistically 
significant for both cell types (hObs and hDFs) (P>0.05). 
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3.1.3 Cell viability of hObs and hDFs 
P-PRP did not show any cytotoxic effects on both cell types. In fact, MTT analysis 
documented that hOb viability increased of 1.8-fold after 12 days of P-PRP culture, 
while in standard condition it was improved by 1.9-fold. (Fig. 10A) (P<0.05). hDFs 
grown for 12 days in the presence of P-PRP achieved a 7.8-fold cell viability increase 
compared with day 5, whereas in CTRL condition it just improved 2.4-fold (Fig. 10B). 
 
Figure 10A. The effect of P-PRP on 
hOb viability. 
 
 
Figure 10B. The effect of P-PRP on 
hDF viability. 
 
 
 
3.1.4 Osteogenic differentiation of hObs 
Alkaline phosphatase activity (ALP) was assessed in hObs induced to osteo-
differentiate for 7 and 14 days in the presence of 2.5% P-PRP. The decision of choosing 
P-PRP concentration of 2.5% was related to our previous findings documenting that 
culture medium supplemented with 2.5% P-PRP was sufficient to maintain cells as the 
standard condition [75]. 
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hObs treated with differentiation (OSTEO) and P-PRP medium showed a similar 
behaviour at 7 days of culture with a minimal detection of ALP activity (Figure 11 left 
panel). ALP activity slowly increased in response to OSTEO and P-PRP medium, with 
the highest point at 14 days (approximately 4-fold increase compared to day 7). The 
additional presence of P-PRP in OSTEO medium did not further stimulate the enzyme 
activity either at day 7 and 14 compared to P-PRP control medium. By the contrast, 
hObs treated with OSTEO medium showed the greatest increase of ALP activity at day 
14 (Figure 11, right panel).  
 
 
Figure 11. The effect of P-PRP on osteo-differentiation of hObs. ALP activity was 
assessed at 7 and 14 days after 2.5% P-PRP incubation. Alkaline phosphatase activity is 
expressed as U/mg proteins. 
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3.2 Randomized clinical study 
3.2.1 Patient population and intervention characteristics 
Study population of this randomized clinical study included 45 patients (26 women, 19 
men, mean age at the implant surgery 51.63 years, range 31-77 years) that were 
followed up to three years after prosthesis loading.  
Baseline demographic details of patients are summarized in Table 4; mean age at 
implant surgery, gender, medical conditions, smoking status did not show any 
significant differences between groups.  
Sinus lift group: 18 patients were allocated to the graft group (4 of which underwent 
simultaneous bilateral sinus augmentation whereas other 3 patients underwent 
bilateral augmentation with separate surgical procedures). The total number of 
augmented sinuses was 25 and received a total number of 58 implants (57 of which 
were equal or longer than 10 mm; 12 implants out of 58 were immediately inserted 
after the sinus augmentation). 
Short implant group: 27 patients were allocated to the short implant group and 
received 65 implants, 42 of which were shorter than 8.5 mm.  
Characteristics of interventions are reported in Table 5 whereas position and number 
of inserted implants in Figure 12. In Table 6 patient platelet counts, performed on 
baseline blood samples and on final P-PRP products, are shown.  
  
	 42	
  
Table 4. Demographic details of the study population 
 SLI  
group 
SI  
group 
Total p-Value 
No. of implants  57(58) 
25 augmented sinus 
42(65) 99(123)  
No. of patients 18* 27 45  
Age at implant surgery 
Mean SD (range) 
 
51.05 ± 10.64  
(36-68) 
 
52.21± 10.42  
(31-77) 
  
0.69 
 
Gender 
F 
M 
 
10 
8 
 
16 
11 
 
26 
19 
 
1 
 
Smoking status 
Non smokers 
Former smokers 
Smokers 
Light smokers 
Heavy smokers 
(>10 al die) 
 
13 
2 
3 
2 
1 
 
20 
0 
7 
2 
5 
  
0.72 
 
ASA  
I 
II 
 
17 
1 
 
24 
3 
 
39 
4 
 
0.63 
 
SLI: Standard Length Implants; SI: Short Implants. 
In brackets are reported the total number of implants inserted.  
*7out of 18 patients underwent a bilateral sinus lift augmentation procedure 
Table 5. Intervention characteristics 
 SLI group SI group 
  Tot. n. of patients 18 (25 sinuses) 27 
  Tot. n. of prosthesis 26 29 
  N. of inserted implants 58 65 
  N. of Standard/ Short implants 57/1 23/42 
  Average n. Tot/SLI/SI implants 3.22/3.17/0.05 2.41/0.85/1.56 
  Mean length of placed implants 11.47 ± 0.63 8.05 ± 0.59 
  N. of 3.75 mm-diameter implants 10 9 
  N. of 4 mm-diameter implants 38 28 
  N. of 4.5 mm-diameter implants 9 5 
  N. of single-tooth prosthesis 7 6 
  N. of fixed-partial prosthesis 18 20 
  N. of fixed-full prosthesis 1 3 
SLI: Standard Length Implants; SI: Short Implants. 
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Figure 12. Implant site 
distribution. 
In the upper panel is represented 
the short implant group whereas 
in the lower panel is represented 
the Standard Length implants 
group. 
 
 
 
 
 
 
 
 
 
Table 6. Patient platelet counts 
 Standard Length Implants 
group 
Short Implants  
group 
Mean baseline platelet 
concentration (103/µl) 
240.83 ± 45.81 251.82 ± 55.80 
Mean P-PRP platelet 
concentration (103/µl) 
303.70 ± 131.22 298 ± 155.01 
Mean increase of platelet 
concentration 
1.30 ± 0.59 1.17 ± 0.53 
P-PRP: Pure-Platelet Rich Plasma 
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3.2.2 Implant and prosthesis survival rate 
All the examined implants were osseointegrated and clinically stable during the study 
period of 3 years, leading thus to a 100% implant survival rate. Table 7 showed the life 
table analysis on implant basis. No prosthetic complications occurred during the study 
period rendering a prosthetic survival rate equal to 100%. No biological complications 
were registered intrasurgically and post-surgically. 
Table 7. Life table analysis on implant basis 
Years N. of 
patients 
N. of 
implants 
Failed implants Lost to f.u. ISR  
% 
CSR 
% 
Standard Length Implants group 
Insertion to 
1 
18 57 0 0 100 100 
1-2 17 55 0 2 100 100 
2-3 12 38 0 17 100 100 
Short Implants group 
Insertion to 
1 
27 42 0 0 100 100 
1-2 27 42 0 0 100 100 
2-3 24 32 0 10 100 100 
ISR Interval survival rate; CSR Cumulative survival rate 
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3.2.3 Peri-implant marginal bone level changes 
Radiographic peri-implant bone level changes for both groups are reported in Table 8. 
No significant changes in marginal bone level at both mesial and distal implant aspect 
were observed between the two groups from implant insertion to 1 year of follow-up. 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. X-rays taken after implant insertion (left panel) and at the prosthesis 
delivery (right panel) of two representative cases. (Upper panel: short implant group, 
lower panel: standard length implant).  
Table 8. Differences in marginal bone level between implant placement and 1 
year of follow-up 
Short Implants group 
Mean mesial value ± SD Mean distal value ± SD 
-0.801 ± 1.52* -0.836 ± 1.53* 
Standard Length Implants group 
Mean mesial value ± SD Mean distal value ± SD 
-1.044 ± 0.46** -0.930 ± 0.65** 
p=0.73 p=0.89 
Negative numbers indicate bone loss 
* These data are relative to short implants only 
** These data are relative to standard length implants only 
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3.2.4 Evaluation of clinical parameters  
Clinical assessments are reported in Table 9. No significant differences neither intra-
groups and inter-groups were reported. The only finding to point out is that the 
presence of bleeding on probing and inflammation were nearly to be statistically 
significant in standard length implants group when comparing the two time points 
considered. 
  
Table 9. Clinical outcomes on implant basis at 1 and 3 year after loading 
 SI group SLI group  
 1y 3y p-value 
1y vs. 3y 
1y 3y p-value 
1y vs. 3y 
p-value 
SI vs. LI 
  1y    3y 
Plaque 1  
(41) 
2 
 (30) 
.27 6*  
(51) 
2  
(51) 
.27 .23 .63 
BoP 1  
(41) 
1  
(31) 
1 5*  
(52) 
0  
(53) 
.06 .24 .38 
Inflammation 0  
(42) 
1  
(31) 
.33 5*  
(52) 
0  
(53) 
.06 .07 .38 
Peri-implant 
radiolucency 
0  
(42) 
0  
(32) 
1 0  
(57) 
0  
(53) 
1 1 1 
Prosthesis mobility 0  
(42) 
0  
(32) 
1 0  
(57) 
0  
(53) 
1 1 1 
SI=Short Implants; SLI= Standard Length Implants; BoP= bleeding on probing 
In brackets are reported the number of implants with absence of plaque, bleeding on probing, 
inflammation, peri-implant radiolucency and prosthesis mobility.  
*Same implants in one patient with full-arch prosthesis 
No statistically significant differences within each group as well as no significant differences 
between two groups at both time periods were reported. 
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Chapter IV: 
Discussion 
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The use of short implants has been proposed as a therapeutic alternative to bone 
augmentation techniques followed by insertion of standard-length implants, when the 
posterior region of maxillae has a reduced ridge height. There is no agreement on the 
definition of a short implant: some authors consider an implant as short when its 
length is inferior to 10 mm [85,86] whereas for others, implant length must be inferior 
or equal to 8 mm [67,68,70,87]. In the present randomized clinical study implants long 
between 8.5 and 6.5 mm were considered short and implants with a length superior or 
equal to 10 mm as standard.  
The results of the clinical part of the study confirmed the predictability and efficacy of 
short implants in the treatment of atrophic maxillae in the medium/ long-term follow-
up. The first null hypothesis was accepted since no differences were found in 
prosthesis and implant survival rates between short and standard implants, both 
inserted during surgeries performed with P-PRP. Furthermore, excellent prosthesis 
and implant survival rates (100%) were reported up to three years after loading in both 
groups. Same high implant survival rates were also documented in other RCTs with 
the same study design as the present study, but a shorter follow-up [71,88-90]. Findings 
coming from recent systematic reviews and meta-analyses were in line with our results 
describing a high prosthesis and implant survival rates for both procedures with no 
significant differences [67,69,70]. Analysis of pooled data of a systematic review 
conducted by Thoma and coll. for EAO working group [67], documented a 99.5% 
survival rate for standard implants in augmented sinus and 99.0% for short implants 
during for a follow-up of 16-18 months [71,89-92], while for shorter follow-up (8-9 
months) a 100% survival rate for standard implants and 98.2% for short implants was 
documented [88,93,94].  
Short implants were expected to have more failures than the standard ones because of 
their theoretical unfavourable mechanical properties [95]. One of the supposed reasons 
may be related to the fact that short implants, having less implant surface, have a 
smaller available contact area with bone tissue and this might compromise the 
achievement of an optimal stability during the osseointegration process, that is closely 
related to the implant success. In case of peri-implant bone resorption, short implants 
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may present a higher risk of mobility than standard length implants. Besides, short 
implants are mostly inserted in posterior regions of the jaws where the bone quality is 
poor, especially in the maxilla [85]. However, results of the present study did not 
demonstrate this negative association between short implants and survival rate, 
reporting a 100% of survival rate for short implants placed in conjunction with P-PRP. 
All implants used in this study, independently of the length, had a micro-rough acid-
etched surface and were humidified with P-PRP, prior to insertion. It is claimed that 
liquid P-PRP, when applied to such type of implant, adsorbs to its surface and forms a 
layer rich of growth factors and other molecules that entirely cover it creating thus a 
dynamic surface coating with biological activity [50,96]. In this way, P-PRP represents 
the initial contact between the surrounding bone tissue and the implant. Consequently, 
due to its content rich of active molecules able to interact with cells in the surrounding 
tissues, P-PRP triggers recruitment, attachment, proliferation and differentiation of 
osteoprogenitor cells as well as osteoblasts.  
In-vitro results of the first part of this thesis confirmed the ability of P-PRP to promote 
vitality and growth of human osteoblasts and human dermal fibroblasts, essential cells 
for bone and soft tissue healing [84]. Furthermore, our results demonstrated that P-PRP 
has a negligible role in osteoblasts differentiation. Other cell-based studies proved that 
PRP had stimulatory effects on migration, proliferation and osteo-differentiation of 
osteoblasts [97-99]. Several animal studies have been conducted to assess the effects of 
PRP on the implant osseointegration process, through histological and 
histomorphometrical evaluation, but controversial results have been reported. In fact, 
some studies could not demonstrate any advantages of PRP over control groups not 
using PRP regarding the promotion of a faster bone formation or a higher bone-
implant contact [47-49]. By contrast, significantly higher percentage of bone-implant 
contact were reported in implants coated with liquid PRP compared to those not PRP-
bioactivated through histomorphometric analysis after 6-8 weeks following implant 
insertion [50-52]. Furthermore, a layer of liquid-PRP sprayed onto the implant surface 
before insertion showed a tendency to increase the bone apposition to roughened 
titanium implants during early healing phase [53,54]. All of these findings may 
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therefore support the clinical use of PRP during oral bone regenerative procedures 
where it is required differentiation and proliferation of bone cells at the site of surgery. 
The second null hypothesis was also accepted since no differences in marginal bone 
loss, complications and clinical parameters (bleeding on probing, inflammation and 
plaque) were observed between the two treatment groups. Few other RCTs, with a 
similar study design, reported marginal bone level changes around short implants and 
standard implants placed in augmented sinus, concluding with a no statistically 
significant difference between the two groups [89,90,92]. In particular, in the present 
study, the observed mean marginal bone loss, at 12 months after loading, was -0.818 
mm and -0.987 mm for short and standard implants, respectively. Pistilli and coll. 
reported a slightly higher marginal bone loss at 12 months of follow-up [89,92], 
whereas Guljé and coll. reported a mean loss of -0.1 mm for both groups at 18 months 
of follow-up [90]. 
In this study, no biological nor prosthetic complications occurred in both groups. 
However, a recent meta-analysis and a systematic review evidenced that short 
implants are associated with a lower risk of complications compared to standard 
implants inserted in augmented sinus [67,70]. This could be due for example to 
intrasurgical complications like the Schneiderian membrane perforation that may 
commonly occur during the procedure of sinus floor elevation procedure. However, in 
the present RCT no perforations occurred during the sinus surgeries performed. One 
possible explanation may be related to the systematic use of P-PRP clot during these 
procedures, as its mechanical and biological properties might have avoided that 
occurrence. P-PRP clot, being of elastic consistency and adhering tightly to the sinus 
membrane, may allow a gently detachment of the membrane in a non-traumatic way. 
In fact, P-PRP clot was positioned below the Schneiderian membrane and then 
compressed favouring the detachment due to its hydraulic pressure reducing thus the 
forces. After completing the lifting procedure, P-PRP clot remains attached to the sinus 
membrane continuing to protect and reinforce it [83]. Furthermore, there is evidence 
that P-PRP clot due to its above-mentioned cohesive properties may effectively be used 
for intrasurgical management of sinus membrane perforation, allowing safe 
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completion of the surgical procedure [83]. In this study, activated P-PRP was combined 
with bone substitute granules forming a compact mixture that facilitates graft 
manipulation ensuring therefore an easier and more precise graft application in the 
sinus cavity, without material dispersion. The latter property is particularly useful as, 
in case of a membrane perforation, it is avoided the escape of some bone graft granules 
into the sinus, making the graft application safer. Moreover, this solid mixture may 
reduce the risk of perforations caused by the sharpness of the granules.  
From the biological point of view, combining P-PRP which has osteoinductive 
properties, on either differentiated osteoblasts and undifferentiated mesenchymal stem 
cells [75,97-102], with osteoconductive bone substitute, may act as an adjunctive 
stimulus that may speed up the graft maturation [1,103,104]. Marx [1] documented, 
through histologic and histomorphometric analysis, an increased bone maturation rate 
and greater bone density when PRP was mixed with bone graft compared with graft 
without PRP. Findings coming from some systematic reviews could not clearly 
demonstrate the beneficial effect of PRP on bone graft healing enhancement in 
maxillary sinus augmentation [43-45]. However, in another meta-analysis of eight 
controlled clinical studies, PRP yielded a significantly greater bone formation in those 
PRP-treated sinuses than control sinuses augmented without PRP [46]. As also 
highlighted in those reviews, much of the discrepancy in observed results can be 
attributed to the adoption of different techniques for the preparation of the platelet 
concentrate. Unless standardized techniques will be developed and used, a quote of 
variation due to the PRP preparation procedure must be taken into account in reviews 
comparing the effect of platelet concentrates as an adjunct to surgical applications. 
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Chapter V: 
Conclusions 
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The present thesis has the characteristic of being composed of two different parts, a 
pre-clinical study and a randomized clinical one, that had as the main central theme 
the evaluation of the biological properties of a platelet concentrate, Pure-Platelet Rich 
Plasma. 
The first part of the thesis focused on cellular biological stimulating properties of P-
PRP. Findings coming from this part demonstrated the proliferative capacities of P-
PRP on human osteoblasts and human dermal fibroblasts. However, further studies 
are needed to demonstrate the osteo-differentiation stimulus of P-PRP.  
The second part of the thesis focused on clinical and radiographic evaluation of the use 
of P-PRP in the management of atrophic posterior maxillae needing an implant 
rehabilitation. Results of this part, showed that both procedures, namely short implants 
and standard length implants in association with maxillary sinus augmentation 
performed with the adjunct of P-PRP, were safe and successful, showing comparable 
outcomes in the rehabilitative treatment of edentulous posterior maxilla with a 
reduced height, during the observational period of 3 years after loading. The use of P-
PRP did not shift the balance toward one technique over the other one, but it may have 
contributed to make these procedures similarly effective in term of clinical and 
radiographic outcomes. In both groups P-PRP was used to humidify the implant 
surface and in addition, in standard implant group, P-PRP was mixed with bone graft 
materials. Since similar outcomes were reported for both approaches, the most cost-
effective treatment appears to be the appropriate and advocated. Therefore, restoring a 
dentition that avoids the surgical procedure of sinus augmentation should be 
considered and recommended since it is associated with an increased treatment and 
surgical time and post-operative morbidity [71]. Of course, it must always be kept in 
mind that the treatment choice must take into account not only the clinical evidence 
and the cost-effectiveness ratio, but also the patient’s preferences and the clinician’s 
skills, as recommended by the evidence-based medicine concept. 
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